SCHEMBL30740911

SCHEMBL30740911

CNCC#Cc1ccccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.46
GRM5 P41594 2/20 0.42
TAAR1 Q96RJ0 1/20 0.41
CYP2A6 P11509 1/20 0.41
CYP2C9 P11712 1/20 0.41
CHRNB2 P17787 1/20 0.41
CYP2B6 P20813 1/20 0.41
CYP2C19 P33261 1/20 0.41
CHRNA4 P43681 1/20 0.41
PTGDR2 Q9Y5Y4 4/20 0.39
HCAR2 Q8TDS4 1/20 0.38
FFAR1 O14842 1/20 0.37
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
IKBKB O14920 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11237484 0.79 KCNH2 (0.48) KCNH2GRM5CYP2C19PTGDR2HCAR2
SCHEMBL3351674 0.77 PTGDR2 (0.46) KCNH2GRM5CYP2C9CYP2C19PTGDR2
SCHEMBL30780880 0.77 PTGDR2 (0.46) KCNH2GRM5CYP2C9CYP2C19PTGDR2
SCHEMBL11234645 0.76 KCNH2 (0.46) KCNH2GRM5CYP2C9CYP2C19PTGDR2
SCHEMBL8302074 0.75 KCNH2 (0.44) KCNH2GRM5PTGDR2HCAR2FFAR1
SCHEMBL4448140 0.75 KCNH2 (0.61) KCNH2GRM5CYP2A6PTGDR2FFAR1
SCHEMBL30707788 0.75 KCNH2 (0.61) KCNH2GRM5CYP2A6PTGDR2FFAR1
SCHEMBL11226589 0.74 KCNH2 (0.44) KCNH2GRM5PTGDR2HCAR2FFAR1
SCHEMBL11227888 0.73 CYP3A4 (0.47) KCNH2GRM5CYP2C9CYP2C19PTGDR2
SCHEMBL18917798 0.72 ALDH1A1 (0.47) KCNH2GRM5CYP2C9CYP2C19PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035341-A1 FTO INHIBITORS RPXDS CO LTD (CN) 2026-02-05 US disclosed
EP-4561975-A1 FTO INHIBITORS RPXDS Co., Ltd (CN) 2025-06-04 EP disclosed
CN-119546566-A FTO inhibitors 瑞璞鑫(苏州)生物科技有限公司 2025-02-28 CN disclosed
WO-2024022491-A1 FTO INHIBITORS RPXDS CO., LTD (CN) 2024-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035341-A1 FTO INHIBITORS FTO, LDLR, GPR119 KCNH2 2351/4885GRM5 2261/4885TAAR1 228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.